Frontier Biopharma, Parent Company of Zdravlje AD, Signs Landmark MoU with SK Bioscience and Government of Serbia to Establish a European Vaccines Development and Manufacturing Hub in Serbia


[Belgrade, Serbia, 8 September 2023] Frontier Biopharma Limited today announced the signing of a Memorandum of Understanding (“MoU”) between the Government of Serbia, SK Bioscience and Frontier Biopharma to establish a vaccines development and manufacturing hub in Serbia.

The MoU signing ceremony was held at the SK Bioscience headquarters in the Republic of Korea and attended by Ana Brnabić, Prime Minister of Serbia, Nemanja Grbicć, Serbian ambassador in South Korea, Kiren L. Naidoo, CEO of Frontier Biopharma Ltd., Jae-Woong Lee, Korean ambassador in Serbia, Chang won Chey, Vice Chairman of SK discovery, and Jaeyong Ahn, CEO of SK bioscience.

Along with the MoU, the Serbian government, SK Bioscience, and Frontier Biopharma agreed to sign a contract within the year for collaborating to establish vaccine development and manufacturing facilities in Serbia. The scope of the project will cover both routine and next generation, premium vaccines for the prevention and treatment of life-threatening diseases.

According to the MoU, SK Bioscience will utilize its vaccine R&D, manufacturing, and commercialization capabilities for strengthening the vaccine manufacturing environment to a global-certified level, transferring technologies and know-how for pandemic preparedness, commercializing products, training human resources, and supporting the vaccine R&D in Serbia. Frontier Biopharma will leverage its sterile production expertise to operate the development and manufacturing hub and commercialise products across the region and international emerging and European markets.

Kiren L. Naidoo, CEO of Frontier Biopharma said, As the parent company of Zdravlje AD, one of the most established pharmaceutical manufacturers in Serbia, we are delighted to be partnering with the Government of Serbia and SK Bioscience on this landmark project. SK Bioscience has a world-class vaccine development and manufacturing platform which delivers access to innovative, next-generation vaccines that prevent and treat life-threatening diseases.  Over the next year we will work closely with our partners to establish a hub that will serve Serbia and international markets with products of the highest quality.

About Frontier Biopharma and Zdravlje AD

Frontier Biopharma Limited, headquartered in the United Kingdom, is the parent company of Zdravlje AD, one of the most established pharmaceutical manufacturers in Serbia, established in 1953. The Company supplies approximately 40 markets around the world (including the EU, UK, Asia-Pacific, South Africa and Latin America) with world-class pharmaceutical products from its EU-GMP approved facilities in Leskovac, Serbia. More information can be found at

About SK Bioscience

SK Bioscience is an innovative vaccine and biotech company, committed in vaccine development and manufacturing to enable more equitable access of vaccines in the world. In leveraging strengths on cutting-edge technologies, SK bioscience has been dedicated to promoting human health from prevention to cure across the globe. With cooperation of domestic and international governments, regulatory agencies, healthcare providers, doctors and medical experts, all of the SK colleagues are passionately committed to providing high-quality vaccines to those who need them and better public healthcare solutions.

SK bioscience Website

SK bioscience Linkedin



+381 60 790 2200

Vlajkova St. 199, 16000 Leskovac, SerbiaMilutina Milankovica Blvd. 23, Belgrade, Serbia